FDC Ltd Valuation Shifts to Expensive Amidst Mixed Market Returns

Valuation Metrics Reflect Elevated Pricing

As of 2 Feb 2026, FDC Ltd trades at ₹378.00, marginally up 0.17% from the previous close of ₹377.35. The stock’s 52-week range spans ₹358.95 to ₹528.30, indicating a significant contraction from its peak. The company’s P/E ratio currently stands at 27.30, a level that has shifted its valuation grade from fair to expensive. This is a critical development given that the P/E ratio is a primary gauge of market expectations for future earnings growth.

Similarly, the price-to-book value ratio has risen to 2.53, reinforcing the notion that the stock is trading at a premium relative to its net asset value. Other valuation multiples such as EV/EBITDA at 20.92 and EV/EBIT at 26.65 also suggest a stretched valuation compared to historical norms.

Peer Comparison Highlights Relative Overvaluation

When benchmarked against key peers in the Pharmaceuticals & Biotechnology sector, FDC Ltd’s valuation appears less compelling. For instance, Gland Pharma and J B Chemicals & Pharmaceuticals are classified as very expensive with P/E ratios of 34.9 and 39.16 respectively, while Emcure Pharma and Wockhardt also trade at expensive multiples. However, FDC’s P/E is still lower than these peers, which may indicate some relative value, but the overall expensive grade signals caution.

Notably, Astrazeneca Pharmaceuticals and Pfizer, global giants in the sector, trade at significantly higher P/E ratios of 92.79 and 29.33 respectively, reflecting their dominant market positions and growth prospects. Yet, these companies also command higher quality grades and stronger financial metrics, which justify their premium valuations.

Financial Performance and Quality Metrics

FDC Ltd’s return on capital employed (ROCE) and return on equity (ROE) stand at 10.64% and 9.27% respectively, indicating moderate profitability but lagging behind some of its more efficient peers. The absence of a dividend yield further limits income appeal for investors seeking steady returns.

The company’s PEG ratio is reported as zero, which may reflect either a lack of meaningful earnings growth projections or data unavailability, adding to the uncertainty around future valuation support.

Stock Performance Versus Sensex

Examining FDC Ltd’s stock returns relative to the Sensex over various time frames reveals a mixed picture. Over the past week, the stock outperformed the benchmark with a 2.43% gain versus Sensex’s 1.00% decline. However, over longer periods, the stock has underperformed significantly. Year-to-date, FDC is down 10.70% compared to Sensex’s 5.28% loss, and over the past year, the stock has declined 20.70% while the Sensex gained 5.16%.

Longer-term returns show some recovery, with a 3-year return of 47.60% outperforming the Sensex’s 35.67%, though the 5-year and 10-year returns lag the benchmark substantially. This performance inconsistency may be contributing to the recent valuation re-rating and the downgrade in quality assessment.

Implications of the Strong Sell Mojo Grade

MarketsMOJO recently downgraded FDC Ltd’s Mojo Grade from Hold to Strong Sell on 3 Nov 2025, reflecting deteriorating fundamentals and valuation concerns. The current Mojo Score of 23.0 is among the lowest in the Pharmaceuticals & Biotechnology sector, signalling weak overall quality and limited upside potential.

The downgrade is supported by the company’s market cap grade of 3, indicating a relatively small market capitalisation that may limit liquidity and institutional interest. This combination of factors suggests investors should exercise caution and reassess the risk-reward profile of FDC Ltd in their portfolios.

Sector Outlook and Valuation Context

The Pharmaceuticals & Biotechnology sector remains a dynamic and competitive space, with companies facing pricing pressures, regulatory challenges, and evolving innovation cycles. Valuation multiples across the sector are generally elevated, reflecting growth expectations and defensive qualities amid market volatility.

FDC Ltd’s current valuation, while expensive, is not an outlier but does not offer the premium quality or growth visibility that justifies such pricing. Investors comparing FDC with higher-rated peers may find better risk-adjusted opportunities elsewhere in the sector.

Investor Takeaway

FDC Ltd’s shift to an expensive valuation grade, combined with a Strong Sell Mojo Grade and underwhelming financial metrics, signals a challenging outlook for price appreciation in the near term. While the stock has shown pockets of outperformance in the short term, its longer-term returns lag behind the broader market and many sector peers.

Investors should carefully weigh the company’s valuation against its growth prospects and quality scores before committing capital. Given the availability of higher-rated alternatives within the Pharmaceuticals & Biotechnology sector, a cautious approach is warranted.

Monitoring upcoming quarterly results and sector developments will be crucial to reassessing FDC Ltd’s valuation attractiveness and potential re-rating opportunities.

Summary of Key Valuation and Performance Metrics for FDC Ltd

• P/E Ratio: 27.30 (Expensive)
• Price to Book Value: 2.53
• EV/EBITDA: 20.92
• ROCE: 10.64%
• ROE: 9.27%
• Mojo Score: 23.0 (Strong Sell)
• Market Cap Grade: 3
• 1-Year Stock Return: -20.70% vs Sensex +5.16%

These figures collectively highlight the valuation premium and performance challenges facing FDC Ltd as it navigates a competitive and evolving pharmaceutical landscape.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →